Steps towards implementation of protocolized dose reduction of adalimumab, etanercept and ustekinumab for psoriasis in daily practice

• Main Authors: L.S. van der Schoot (Author), J.J. Janssen (Author), M.T. Bastiaens (Author), A. de Boer-Brand (Author), C. Christiaansen-Smit (Author), D.N.H. Enomoto (Author), R. Hovingh (Author), R.A. Tupker (Author), M.M.B. Seyger (Author), L.M. Verhoef (Author), J.M.P.A. van den Reek (Author), E.M.G.J. de Jong (Author)
• Formato: Livro
• Publicado em: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Background Dose reduction (DR) of adalimumab, etanercept and ustekinumab has proven to be (cost-)effective in psoriasis patients with low disease activity. Further implementation is needed to establish application of DR for eligible patients. Objectives To evaluate the implementation of protocolized...